Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain

Characteristic Spain
n = 119
Other Countriesa
n = 907
Sex, n (%)   
 Female 64 (53.8) 548 (60.4)
 Male 55 (46.2) 359 (39.6)
HAE type, n (%)   
 HAE-1 114 (95.8) 838 (92.4)
 HAE-2 5 (4.2) 69 (7.6)
Median (IQR) age at first symptoms, y 15.0 (5.0–20.0) 12.0 (5.0–18.0)
Median (IQR) age at diagnosis, y 22.3 (13.6–36.0) 20.5 (12.6–32.9)
Median (IQR) time to diagnosis, yb 6.4 (1.0–18.3) 5.4 (0.2–17.0)
Median (IQR) age at enrollment, y 39.3 (27.2–50.4) 39.0 (27.5–51.8)
Median (IQR) age at data extract, y 45.0 (34.0–56.0) 44.0 (32.0–57.0)
Median (IQR) duration of follow-up in IOS, y 5.6 (1.2–7.0) 2.4 (0.4–4.9)
  1. HAE-1/2 HAE due to C1 inhibitor deficiency, IOS Icatibant Outcome Survey
  2. aAustralia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Sweden, and the United Kingdom
  3. bDefined as the difference between age at first symptoms and age at diagnosis